Emad Shash, Leading Cancer Researcher and Director at National Cancer Institute, Cairo University, shared a psot on LinkedIn:
“I am proud to share the publication of our study in Pharmacotherapy, “The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study.”
Paclitaxel-induced peripheral neuropathy remains one of the most challenging toxicities we face in breast cancer care, with a major impact on symptoms, quality of life, and treatment delivery. In our randomized controlled study, losartan showed promising results in reducing and delaying clinically significant neuropathy while improving neurotoxicity-related quality of life and pain outcomes. Importantly, it was also well tolerated.
I am sincerely grateful to my co-authors, Dr Aalaa Mahmoud El-Rifai, BSc., Prof. Hayam Ateyya, Dr Farida Aly Okasha, and Prof Nouran Omar, PhD, for their collaboration, scientific rigor, and commitment throughout this work.
My deepest thanks go to our patients and their families. Clinical research moves forward because of your trust, courage, and willingness to contribute to better care for others.
I also want to thank our whole team for making this work possible, especially our colleagues at the Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University, along with all physicians, clinical pharmacists, nurses, research staff, and collaborators who supported referral, follow-up, and study execution. This publication is a true team effort.
These findings are encouraging, but we acknowledge the need for larger multicenter trials to draw definitive clinical conclusions. Still, this is an important step toward improving supportive care in breast cancer.”
Title: The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study
Authors: Aalaa Mahmoud Ahmed Shawqi Mahmoud, Emad Shash, Hayam Ateyya, Farida A. Okasha, Nouran Omar El Said.
Other articles featuring Emad Shash on OncoDaily.